Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 14/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 5/20 | 1.00 |
| ▸ | ITGA5 | P08648 | 5/20 | 1.00 |
| ▸ | ITGB8 | P26012 | 5/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 4/20 | 1.00 |
| ▸ | ITGA8 | P53708 | 4/20 | 1.00 |
| ▸ | ITGA2B | P08514 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049848 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6679570 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL19090834 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6225944 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6225812 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6805932 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL8334397 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6221693 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6224245 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6682740 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1156999-B1 | METHOD FOR THE PREPARATION OF A CHIRAL-BETA-AMINO ESTER | SEARLE LLC (US) | 2004-11-17 | — | — | EP | disclosed |
| US-6660466-B1 | Reacting reactive appendage compounds such as meta benzylic compounds or alpha-amide compounds with scaffold molecules having reactive functionalities and contacting the intermediate library with a reducing agent | ISIS PHARMACEUTICALS, INC. | 2003-12-09 | — | — | US | disclosed |
| US-20030050250-A1 | Alpha v beta 3 integrin antagonists in combination with chemotherapeutic agents | PHARMACIA CORPORATION | 2003-03-13 | — | — | US | disclosed |
| US-6372719-B1 | 1,4,5,6-TETRAHYDRO-5-HYDROXYPYRIMIDIN-2-AMINE DERIVATIVES ARE ADMINISTERED IN MIXTURE; ANTITUMOR AND ANTICARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | G.D. SEARLE & CO. | 2002-04-16 | — | — | US | disclosed |
| US-6172256-B1 | USING A BLOCKING AGENT; DEBLOCKING WITH TRIMETHYLSILYL IODIDE | G.D. SEARLE & CO. | 2001-01-09 | — | — | US | disclosed |
| US-6100423-A | Amino benzenepropanoic acid compounds and derivatives thereof | G. D. SEARLE & CO. (US) | 2000-08-08 | — | — | US | disclosed |
| US-6013651-A | ANTITUMOR AGENTS; BONE DISORDERS; ANTIARTHRITIC AGENTS; SKIN DISORDERS | G. D. SEARLE & CO. (US) | 2000-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050250-A1 | Alpha v beta 3 integrin antagonists in combination with chemotherapeutic agents | ITGAV, ITGB3, ITGB1 | ITGB3 2/4885ITGAV 1/4885ITGB6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.